$60–110B
annual economic value gen AI could generate across pharma and medical products, with commercial operations as a top impact area [1]
48%
of LSHC board members lack representation in AI and data science — a governance gap directly affecting data strategy [2]
Only 22%
of life sciences leaders say they have successfully scaled AI — highlighting data foundation as the critical bottleneck [3]

Data is the foundational resource of modern life sciences — yet most organizations in the sector are dramatically underutilizing it. Not because they lack data. Life sciences organizations generate extraordinary volumes of data across clinical operations, commercial activities, manufacturing, regulatory affairs, and pharmacovigilance. The problem is that this data is fragmented, inconsistently governed, and inaccessible to the analytical and AI tools that could generate value from it.

A data strategy is the plan for transforming that situation: defining what data assets the organization has, how they will be governed, where they will live, how they will be accessed, and what analytical capabilities will be built on top of them.

The Life Sciences Data Landscape

Clinical and Research Data

Clinical trial data, real-world evidence, biomarker data, genomic data, and laboratory results represent some of the most valuable — and most regulated — data in the life sciences portfolio. CDISC standards (CDASH, SDTM, ADaM) provide structure, but compliance with those standards is inconsistent across vendors and sites. Access controls, audit requirements, and patient privacy obligations under HIPAA, GDPR, and regional equivalents layer significant complexity onto data management.

Commercial and Market Data

Prescription data (IQVIA, Symphony Health), claims data, CRM data, market access and formulary data, and patient support program data collectively form the commercial intelligence picture. These data streams are typically sourced from multiple vendors, delivered in incompatible formats, and updated on different schedules — making integration the central challenge.

Manufacturing and Quality Data

Batch records, environmental monitoring data, equipment performance data, and quality system records are among the most compliance-critical data in the organization. Data integrity requirements under 21 CFR Part 11 and EU GMP Annex 11 impose strict requirements on how this data is created, stored, and accessed.

Pharmacovigilance and Safety Data

Adverse event reports, signal detection analytics, aggregate safety reports, and regulatory submission data for safety are subject to both global regulatory requirements (ICH E2B) and strict timelines for processing and reporting. Data quality failures in pharmacovigilance carry direct patient safety implications and significant regulatory risk.

The Analytics Maturity Model

Analytics capability in life sciences exists on a continuum from basic reporting to AI-powered predictive intelligence. Understanding where your organization sits on this continuum — and where it needs to be to achieve its strategic objectives — is fundamental to prioritizing data strategy investment.

Level 1 — DescriptiveWhat happened? Standard reports, dashboards, KPI tracking.
Level 2 — DiagnosticWhy did it happen? Root cause analysis, drill-down analytics, variance analysis.
Level 3 — PredictiveWhat will happen? Statistical models, forecasting, risk scoring.
Level 4 — PrescriptiveWhat should we do? AI recommendations, optimization models, decision support.
Level 5 — AutonomousSelf-executing decisions within defined parameters. Closed-loop AI systems.

Most life sciences organizations currently operate primarily at Levels 1 and 2. The significant AI and analytics value lies at Levels 3 and 4. Reaching those levels requires intentional investment in data foundation and governance, not just analytics tooling.

Critical Distinction: Organizations frequently attempt to skip the foundation-building work and go directly to predictive analytics or AI implementation. The result is almost always the same: models that look impressive in demonstrations but fail to deliver reliable outputs in production, because the underlying data quality and governance are insufficient to support them.

Data Governance: The Non-Negotiable Foundation

Master Data Management

Master data — the core reference data that other data depends on, including HCP identities, product identities, organizational hierarchies, and geographic definitions — is the most critical governance target. When master data is inconsistent, every downstream data set is affected.

MDM programs for life sciences commercial operations typically prioritize HCP/HCO data as the highest-value target. Aligning HCP identities across CRM, claims, prescription data, speaker programs, medical education records, and sample tracking is a significant data engineering challenge — but organizations that achieve it unlock analytical capabilities that are simply impossible with fragmented HCP data.

Data Quality Management

Data quality management defines the standards, measurements, and improvement processes that ensure data meets fitness-for-purpose thresholds across six dimensions: completeness, accuracy, consistency, timeliness, uniqueness, and validity. Life sciences organizations should establish data quality metrics for their most business-critical data domains and monitor those metrics on a regular cadence.

Data Privacy and Security

Life sciences data governance must incorporate robust privacy and security frameworks that comply with HIPAA, GDPR, state privacy laws, and the emerging international regulatory landscape. This is an ongoing program that requires regular assessment as data assets, processing activities, and regulatory requirements evolve.

Technology Architecture Considerations

Architecture LayerKey PlatformsLife Sciences Considerations
Data IngestionAzure Data Factory, AWS Glue, FivetranVendor data format variability; Part 11 audit requirements for regulated sources
Data StorageSnowflake, Databricks, BigQueryData residency requirements; access control granularity; encryption standards
Data Transformationdbt, Spark, SQLTransformation logic documentation; version control; validation requirements
Analytics and BITableau, Power BI, Veeva Nitro/MyInsightsRole-based access control; promotional compliance for external content
AI and MLAzure ML, SageMaker, Vertex AIModel validation; bias assessment; explainability requirements
Data CatalogCollibra, Alation, AtlanData lineage documentation; sensitivity classification; regulatory reporting

Building Your Data Strategy

A data strategy is most effective when it directly links to business strategy — articulating how data and analytics capabilities will enable specific strategic objectives. Generic data strategy documents that are not grounded in concrete business outcomes rarely drive sustained investment or organizational commitment.

Step 1 — Strategic Alignment: Define the three to five business outcomes that your data strategy must enable. These might include accelerating drug launch commercial performance, improving clinical trial recruitment efficiency, or enhancing pharmacovigilance signal detection sensitivity.

Step 2 — Current State Assessment: Audit your existing data assets, systems, and capabilities against your strategic requirements. Where are the gaps? What data quality and governance improvements are prerequisites for the analytical capabilities you need?

Step 3 — Architecture Design: Define the target data architecture that will support your strategic requirements. Prioritize decisions that provide long-term flexibility over those that optimize for current requirements at the expense of future adaptability.

Step 4 — Roadmap and Sequencing: Sequence your implementation based on value delivery, dependency management, and risk. Build foundation capabilities before advanced analytics. Deliver quick wins that demonstrate value and maintain organizational momentum.

Step 5 — Organizational Capability: A data strategy is only as effective as the people executing it. Define the data literacy, analytical, and engineering capabilities your organization needs. Build a resourcing plan that combines internal development, strategic hiring, and external partnerships.

Sakara Digital Perspective: The most common data strategy failure mode is not technical — it is organizational. Organizations that build excellent data architectures but do not develop the analytical culture, data literacy, and cross-functional collaboration patterns needed to use them effectively consistently underperform against their data investment.

Conclusion

The organizations that will define the competitive landscape of life sciences over the next decade are building their data foundations now. The regulatory complexity, data volume, and analytical sophistication required to compete all require a data strategy that is intentional, governed, and continuously evolved.

The investment is significant — but the cost of not investing is higher. Fragmented, ungoverned data is not just an efficiency problem. In life sciences, it is a patient safety risk, a regulatory risk, and an increasingly serious competitive disadvantage.

Sakara Digital works with life sciences organizations at every stage of data strategy development — from initial assessment and architecture design to implementation support and capability building.